Papyrus Australia Plans 3.33 Million Options Issuance to L39 Broker as Part of Irwin Biotech Loan Agreement

Overview of Papyrus Australia's Business and Financial Strategy

Papyrus Australia Limited, an ASX-listed entity (ACN 110868409, ticker PPY), operates within Australia focusing on corporate and investment ventures. Recent developments in its capital structure, including the Irwin Biotech Loan facility, highlight its strategic financing initiatives. This loan arrangement underscores the company’s engagement with specialized funding solutions to support its operational goals. The broker commission structure tied to this facility emphasizes the transaction’s significance in Papyrus Australia's financial framework.

The company's method of compensating brokers through equity options aligns with industry norms, enabling brokers to benefit from potential share price appreciation while aligning their interests with shareholders. The AUD 50,000 valuation of broker services reflects the scale of financial activity related to the Irwin Biotech Loan. Investors should consider this capital management approach when assessing Papyrus Australia's financing and operational strategies.

Details of Option Terms and Exercise Conditions

The 3,333,333 proposed options grant L39 the right to convert each option into one fully paid ordinary share of Papyrus Australia at an exercise price of AUD 0.015. These options will expire three years from the grant date of 5 November 2026, providing a defined timeframe for exercising conversion rights. This structure incentivizes the broker by linking compensation to the company’s share price performance over the term.

The exercise price of AUD 0.015 sets the economic threshold at which the options gain value. Should Papyrus Australia's share price exceed this level within the three-year period, L39 may exercise the options to acquire shares at a discount. Upon exercise, the options convert into fully paid ordinary shares, granting L39 unencumbered equity ownership. This arrangement ensures transparency regarding ownership implications for both the broker and existing shareholders.

Valuation of Non-Cash Consideration and Broker Service Arrangement

The options are issued as non-cash compensation for L39’s services associated with the Irwin Biotech Loan facility. Papyrus Australia has assigned a value of AUD 50,000 to this broker remuneration, reflecting the commercial worth of services provided in facilitating the loan. This equity-based compensation aligns with common practices where brokers receive options proportional to their advisory or arrangement contributions. Opting for options over cash aids in preserving company capital while aligning incentives.

The Irwin Biotech Loan facility is a significant financing event for Papyrus Australia, with the AUD 50,000 broker service valuation indicating the complexity and importance of the transaction. Engaging professional intermediaries to secure debt capital is a standard practice among ASX-listed companies aiming to optimize capital structures. The issuance of broker options linked to this facility demonstrates the company’s approach to balancing cash flow management with securing expert financial services.

Shareholder Approval Requirement Under ASX Listing Rule 10.11

Issuance of the options requires shareholder approval under ASX Listing Rule 10.11, applicable when securities are issued to parties related to the broker. Papyrus Australia has scheduled this approval vote for 29 October 2026, allowing shareholders to evaluate and vote on the proposal. This process ensures transparency and fairness prior to the issuance. The date represents the anticipated decision point as detailed in the company’s update.

This approval requirement reflects governance standards protecting minority shareholders when related parties receive securities. Papyrus Australia’s adherence to this rule highlights its commitment to regulatory compliance and transparent capital management. A forthcoming General Meeting Notice will provide shareholders with comprehensive details to facilitate informed voting. This governance framework ensures the option issuance undergoes proper scrutiny before the proposed grant date of 5 November 2026.

Timeline for Option Grant and Expiry

The options are scheduled to be issued on 5 November 2026, marking the start of the three-year term ending on 5 November 2029. This timeline defines when L39’s option rights commence and the period during which exercise is permitted. The issuance date follows the shareholder approval process and finalization of transaction documentation.

The close timing between the shareholder approval date (29 October 2026) and the option grant date (5 November 2026) facilitates prompt execution upon receiving consent. For investors tracking Papyrus Australia's capital activities, the 5 November 2026 issuance is a key corporate event impacting the company’s share and option registers.

Classification and Quotation Status of the New Option Class

The options constitute a new class of securities not previously listed on the ASX or included in Papyrus Australia's option register. The ASX will assign a new class code upon completion of the quotation process. However, Papyrus Australia has elected not to seek ASX quotation for these options, maintaining them as unquoted securities. This simplifies issuance while preserving their role as equity compensation instruments.

By not pursuing ASX quotation, these options will not be tradable on secondary markets, limiting transferability and liquidity. This approach is typical for broker compensation options, where the issuer prefers a controlled, non-transferable arrangement. The new class designation ensures these options are distinct from other classes issued by Papyrus Australia. Despite being unquoted, the options retain full economic rights to convert into ordinary shares under the specified terms.

Security Holder Approval and Compliance With Listing Rules

Papyrus Australia confirms compliance with ASX Listing Rules by securing shareholder approval for this related party transaction, foregoing reliance on placement capacity exemptions. This approach guarantees all shareholders can review and vote on the option issuance, reinforcing governance standards.

The shareholder approval determination is due by 29 October 2026, with no approval granted at the time of the company’s update. This forthcoming meeting underscores the company’s commitment to transparent capital management and prioritizing shareholder consent over administrative expediency.

Disclosure of Material Terms and Option Features

The company has disclosed key terms of the options in line with ASX requirements. The exercise price of AUD 0.015 and three-year expiry from 5 November 2026 define the options’ economic profile. Each option entitles L39 to one fully paid ordinary share upon exercise, with no additional conditions beyond the exercise price. Further details will be provided in the General Meeting Notice to assist shareholder decision-making.

Options will rank equally from issue date, ensuring clarity on their legal standing within the capital structure. Denominated in Australian dollars, the terms align with Papyrus Australia's primary market and shareholder base. These disclosures provide transparency for shareholders and market participants to assess the fairness and impact of the issuance.

Impact on Capital Structure and Shareholder Equity

The issuance of 3,333,333 options will increase Papyrus Australia's equity base upon exercise, potentially diluting existing shareholders. Full exercise would result in 3,333,333 new ordinary shares issued at AUD 0.015 each, generating AUD 50,000 in proceeds. Actual dilution depends on L39’s exercise decisions and market conditions during the three-year term.

Issuing options as non-cash compensation reflects Papyrus Australia's strategy to conserve cash while securing expert broker services. For shareholders, the capped number of options limits potential dilution. The exercise price sets a threshold for economic benefit, requiring significant share price appreciation for option exercise to be advantageous. This structure enables investors to model dilution scenarios based on share price movements and exercise likelihood.